3M UNPROTECTED LEAD WIRES WILL BE DISCONTINUED JAN. 1
This article was originally published in The Gray Sheet
Executive Summary
3M UNPROTECTED LEAD WIRES WILL BE DISCONTINUED JAN. 1 and replaced with a "safety version" of the wires, the company noted in recent comments to FDA on the agency's proposal to develop a performance standard for electrode lead wires. 3M Health Care is "phasing out" unprotected lead wires despite the fact that the company "continues to get requests for exposed [unprotected] metal single and twin pin lead wires" and "does not anticipate that these requests will diminish in the near future."
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.